Mission: The Clinical Endocannabinoid System Consortium is a non-profit research organization that studies the safety and efficacy of community-accessible Cannabis products in collaboration with diverse scientific partners.
CESC is Dedicated to Cannabis Product Safety, and Patient Access Strategies that
Support the Full Development Lifecycle
The CESC is a leading provider of Cannabis science research. Through an established consortium of scientists, the CESC works to make Cannabis safer and more accessible to the public. Our diverse organization helps bridge the gap between Cannabis product development and delivery. We have a proven ability to generate authoritative, real-world evidence of product effectiveness, safety, and value.
Developing a Cannabis product through commercialization, and demonstrating its post-launch value and safety is a complex journey. Regulatory hurdles and decision-making increase complexity. CESC aligns Cannabis communities, scientific expertise, and industry insight to help make informed decisions early in the product development journey and, ultimately, validates products to improved outcomes. Our science focuses on validating high end, well-produced Cannabis products at good price point.
The CESC’s Dosing Project is a real-world data registry. Initiating the Dosing Project quickly establishes a core strength – the generation, analysis, and communication of real-world evidence throughout the product lifecycle. Investigators, Dr. John S. Abrams, and Dr. Jean Talleyrand, demonstrate innovation in their commitment to working with Cannabis prevalent communities, governments, and academic institutions. They recognize the opportunity to meet the need for scientific evidence in a developing industry.
The most successful journeys start with great maps. CESC’s industry-leading experts work in unison to effectively navigate the product lifecycle mapped by Characterization, Categorization, Stratification, Correlation and Certification. Potency Assays, Process Control, and Flight Concepts, offer Sponsors a competitive edge in a market with stakeholders that require the right evidence at the right time. We understand what it takes to solve the many-to-many relationships inherent in botanical product development.
We are an experienced committee of scientists who hold the passionate belief that the pursuit of knowledge involves collaboration with diverse communities.
Meet Our Founders
John Abrams, Ph.D., Chairman, CSO
Jean Talleyrand, M.D., CTP
CESC Co-Founder. Rated 2020 top Cannabis Scientists by Cannabis Science magazine. Dr. Abrams entered the Cannabis industry after a successful career investigating antibodies as therapeutic agents. His Cannabis industry accomplishments include developing a novel chemotyping algorithm for Cannabis categorization. Dr. Abrams has been Scientific Director at the Emerald Science Conference for six years.
CESC Co-Founder. Dr. Talleyrand is the most experienced Cannabis clinician world-wide, In 2004, he founded MediCann, a Cannabis physician referral service providing over one half million patient consultations. Dr. Talleyrand’s first clinical program, the Dosing Project, employs an observational approach to Cannabis study, translating crowd-sourced data in order to elucidate Cannabis dose effect relationships.
Experienced: CESC Founders have a combined 60 years of experience in drug development and clinical observations of Cannabis use
Collaboration: CESC is a consortium of independent organizations and individuals
Transformational: Crowd-source data informs the public and the Cannabis industry on best use practices
Comprehensive: The CESC approach is inherently “meta” and initiates from all facets of the Cannabis experience
Vision: To see a world where Cannabis use is re-established with validated products and practices. To reduce sickness and disease through the investigation of botanical products
Dr. Talleyrand is guided by generational influences in botanical medicine. He credits both his physician father and pharmacist mother as early examples of scientific discipline and rigor. As well, the history of his native, Haiti, is rich in botanical influences. Throughout his career, Dr.Talleyrand focussed on and advocated for community-oriented healthcare in underserved populations. Equipped with this approach, he pioneered medical Cannabis use in California advocating for his first patient in 1998. In 2015, Dr. Talleyrand met Dr. John S. Abrams, a Cannabis enthusiast and experienced innovator in biopharmaceutical drugs. They immediately partnered to form the CESC.
"Medically underserved communities have traditionally relied on self-care alternatives for medicine. Cannabis has been one of those alternatives. Now, it's recognized world-wide as medically beneficial. This is the result of a tenacity in underserved populations. Cannabis scientists can appreciate and benefit from the experience of these populations. In turn, the burgeoning industry can contribute to causes that benefit those who have carried the torch before them."
-Jean L. Talleyrand, M.D., CTP
Dr. Abrams was born with a genetic defect causing compromised vision from an early age. Despite the challenges of living with a disability, he was able to navigate a successful family and career . Cannabis has been a part of his success. Dr. Abrams envisions the development of Cannabis-based medicine as parallel to his early experiences in Immunology which led to discoveries in the now expansive field of bio-similar therapeutics. His recent work in Cannabis science has already been recognized by Cannabis Scientist and identifies him as one of the leading innovators in the field. Dr. Abrams' drive is to continue to make contributions to Cannabis science with the hope of improving the lives of others with disabilities.